Alirocumab reduces total hospitalizations and increases days alive and out of hospital in the odyssey outcomes trial

Background: in ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab was compared with placebo,  added to high-intensity or maximum tolerated statin treatment after acute coronary syndrome in 18 924 patients.

 Alirocumab reduced first occurrence of the primary composite end point-coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or hospitalizations and death and increased days alive and out of hospital (DAOH) and percent DAOH in ODDYSSEY OUTCOMES.